CG Oncology, Inc. Payments to Acquire Investments
CG Oncology, Inc. (CGON) reported Payments to Acquire Investments of $783.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-06
- CG Oncology, Inc. payments to acquire investments for the quarter ending 2026-06-30 was $196.01M, a 16.70% increase year-over-year.
- CG Oncology, Inc. payments to acquire investments for the quarter ending 2026-03-31 was $587.39M, a 62.31% increase year-over-year.
- CG Oncology, Inc. payments to acquire investments for the quarter ending 2025-12-31 was $297.74M, a 37.16% increase year-over-year.
- CG Oncology, Inc. payments to acquire investments for the quarter ending 2025-09-30 was $240.27M.
- CG Oncology, Inc. payments to acquire investments for fiscal 2025 was $1.07B, a 2.10% increase from fiscal 2024.
- CG Oncology, Inc. payments to acquire investments for fiscal 2024 was $1.05B, a 102.07% increase from fiscal 2023.
- CG Oncology, Inc. payments to acquire investments for fiscal 2023 was $517.61M.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $196.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $783.40M 10-Q · filed 2026-08-06 | $1.08B derived: sum of 3 quarters · filed 2026-08-06 | $1.32B derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $587.39M 10-Q · filed 2026-05-08 | $885.13M derived: sum of 2 quarters · filed 2026-05-08 | $1.13B derived: sum of 3 quarters · filed 2026-05-08 | $1.29B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $297.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $538.01M derived: sum of 2 quarters · filed 2026-02-27 | $705.97M derived: sum of 3 quarters · filed 2026-08-06 | $1.07B 10-K · filed 2026-02-27 |
| 2025-09-30 | $240.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $408.23M derived: sum of 2 quarters · filed 2026-08-06 | $770.12M 10-Q · filed 2025-11-14 | $987.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $167.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $529.85M 10-Q · filed 2026-08-06 | $746.92M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-03-31 | $361.89M 10-Q · filed 2026-05-08 | $578.96M derived: sum of 2 quarters · filed 2026-05-08 | ||
| 2024-12-31 | $217.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $1.05B 10-K · filed 2026-02-27 | ||
| 2024-09-30 | $828.87M 10-Q · filed 2025-11-14 | |||
| 2023-12-31 | $517.61M 10-K · filed 2026-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |